SG3 Management’s Cardlytics CDLX Stock Holding History

SG3 Management’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4,000	Closed	-$4.39M	–	1066
2021 Q1	$4.39M	Buy	4,000 +300	+8%	+$396K	0.11%	204
2020 Q4	$5.28M	Buy	+3,700	New	+$3.95M	0.1%	185

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return

SG3 Management's CDLX Position: Q2 2021 in Review

SG3 Management sold out of Cardlytics (CDLX) in Q2 2021, closing a stake of 2,650 shares — an estimated $2.91M sold.

SG3 Management first reported a position in CDLX in Q1 2021 and held it in 1 quarter. The position peaked at $2.91M in Q1 2021. 189 funds tracked by Wall St. Rank hold CDLX as of Q2 2021.

SG3 Management reported no remaining Cardlytics position as of Q2 2021 after selling out during the quarter.
SG3 Management sold 2,650 Cardlytics shares in Q2 2021, an estimated $2.91M.
SG3 Management first reported a position in Cardlytics in Q1 2021 and held it in 1 quarter.
SG3 Management's Cardlytics position peaked at $2.91M in Q1 2021.
189 funds tracked by Wall St. Rank held Cardlytics as of Q2 2021.

Based on SG3 Management's 13F filing for Q2 2021, filed 16 Aug 2021.